Melanoma-associated hypopigmentation: Where are the antibodies?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 6, 1996, Pages 613-618

  Merimsky, Ofer ^a,b,c,d   Shoenfeld, Yehuda ^b,e   Baharav, Ehud ^c,d   Altomonte, Maresa ^f   Chaitchik, Samario ^a,b   Maio, Michele ^f   Ferrone, Soldano ^g   Fishman, Pnina ^c,d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d BAR ILAN UNIVERSITY   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g Oncology Referral Center ^*

Author keywords

Antityrosinase antibodies; Cross antigenicity; Melanoma; Melanoma associated hypopigmentation; Vitiligo

Indexed keywords

ANTIBODY; IDIOTYPIC ANTIBODY; MEMBRANE ANTIGEN; MONOPHENOL MONOOXYGENASE;

ANTIBODY TITER; ANTIGENICITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOPIGMENTATION; MELANOCYTE; MELANOMA; OPTICAL DENSITY; VACCINATION; VITILIGO;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; AUTOIMMUNE DISEASES; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; HYPOPIGMENTATION; MALE; MELANOCYTES; MELANOMA; MELANOMA, EXPERIMENTAL; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED; VACCINATION; VITILIGO;

EID: 0029810236     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199612000-00017     Document Type: Article

References (28)

1. Merimsky O, Shoenfeld Y, Yecheskel G, Chaitchik S, Azizi E, Fishman P. Vitiligo and melanoma associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother 1994;38:411-6.
2. Merimsky O, Shoenfeld Y, Chaitchik S, Fishman P. Antigens and antibodies in malignant melanoma. Tumor Biol 1994;15:188-202.
3. Ferrone S, Kageshita T. High-molecular-weight melanoma associated antigen as a target for active specific immunotherapy: a phase I clinical trial with murine monoclonal antibodies. J Dermatol 1988;15:457-65.
4. Bystryn JC, Rigel D, Friedman RJ, Kopf A. The prognostic significance of vitiligo in patients with melanoma. Arch Dermatol 1987;123:1053-5.
5. Donaldson RC, Canaan SA, McLean R, Ackerman LV. Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery 1974;76:771-8.
6. Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 1983;9:696-701.
7. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983;9:689-96.
8. Laucius JF, Mastrangelo MJ. Cutaneous depigmentary phenomena in patients with malignant melanoma. In: Laucius JF, Mastrangelo MJ, eds. Human malignant melanoma. Philadelphia: Grune and Stratton, 1979:209-25.
9. McBurney EL. Vitiligo: clinical picture and pathogenesis. Arch Intern Med 1979;139:1295-7.
10. Hertz KC, Gazze LA, Charles AB, Kirkpatrick H, Katz SL. Autoimmune vitiligo detection of antibodies to melanin producing cells. N Engl J Med 1977;291:614-1.
11. Moellman GE, Krass P, Halaban R. On the subject of serum antibodies to melanocytes in vitiligo. J Invest Dermatol 1985;84:333-7.
12. Naughton G, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986;15:978-81.
13. Nordlund JJ, Lerner AB. Vitiligo: it is important. Arch Dermatol 1982;118:5-8.
14. Fishman P, Azizi E, Shoenfeld Y, et al. Vitiligo autoantibodies are effective against melanoma. Cancer 1993;72:2365-9.
15. Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol 1989;7:136-45.
16. Gupta RK, Morton DL. Detection of 90KD glycoprotein antigen containing immune complexes in sera of melanoma patients using an enzyme immunoassay. FASEB J 1991;5:A1355.
17. Naughton GK, Eisenger M, Bystryn JC. Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983;158:246-51.
18. Uz-Zaman T, Begum S, Waheed MA. In vitro assessment of T lymphocyte functioning in vitiligo. Acta Derm Venereol (Stockh) 1992;72:266-7.
19. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cells clones from melanoma patients. J Exp Med 1993;177:989-98.
20. Le Poole IC, Mutis T, Van Den Wijngaard RMJGJ, et al. A novel, antigen presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol 1993;151:7284-92.
21. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma associated antigen (HMWMAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89:466-70.
22. Lerner AB, Nordlund JJ. Should vitiligo be induced in patients after resection of primary melanoma? Arch Dermatol 1977;113:421.
23. Lerner AB, Cage CW. Melanoma in horses. Yale J Biol Med 1973;46:646-50.
24. Hornung MO, Krementz ET. Specific tissue and tumor re sponses of chimpanzees following immunization against human melanoma. Surgery 1974;75:477-86.
25. Sohn N, Gang H, Gumport SL, Goldstein M, Depisch LM. Generalized melanosis secondary to malignant melanoma. Cancer 1969;24:897-903.
26. Nishioka K, Romsdahl MM, McMurtrey MJ. Adaptation of tritiated tyrosinase assay to serum tyrosinase and its specific elevation in melanoma. In: Klaus SN, ed. Pigmented cell; vol 5. Basel: Karger, 1979:300-4.
27. Agrup P, Carstam R, Wittbjer A, Rorsman H, Rosengren E. Tyrosinase activity in serum from patients with malignant melanoma. Acta Derm Venereol (Stockh) 1989;69:120-4.
28. Karg E, Hultberg B, Isaksson A, Rosengren E, Rorsman H. Enzyme release from cultured human melanoma cells. Acta Derm Venereol (Stockh) 1990;70:286-90.